PrecisionLife announces appointment of Colin Stubberfield as SVP Drug Discovery to lead development of its precision medicine programs

OXFORD, UK February 21, 2022 – PrecisionLife Limited, a global techbio company driving precision medicine in chronic diseases with drug discovery, clinical development, and healthcare solutions based on its unique insights into disease biology, announces the appointment of Colin Stubberfield, Ph.D. as SVP Drug Discovery. He will be based at the Company’s UK headquarters in Oxfordshire, UK.
Dr Stubberfield brings over three decades experience in leading drug discovery research in the life sciences industry. At PrecisionLife he will be responsible for developing the Company’s pipeline of partnered and in-house discovery programs, validating novel precision therapies and biomarkers, and managing the growing biopharma team and its collaborations with external partners and CROs.
He joins from e-Therapeutics where he was Chief Research Officer, leading the Company’s small molecule drug discovery projects. Colin has built virtual development models, bringing together resources from CROs and in collaboration with pharma partners. He has coordinated diverse teams in successful target identification/validation and drug discovery organizations, from large pharma to small biotechs, including UCB-Celltech, Oxford GlycoSciences, GSK and Wellcome.
Dr Stubberfield, SVP Drug Discovery said: “I believe that our ability to generate patient data has outstripped our ability to interpret it to uncover the drivers of complex diseases. We need more innovative and informative approaches to analysis and patient stratification. I am therefore delighted to be joining the excellent team at PrecisionLife to help fully exploit its combinatorial analytics platform and establish in-house drug discovery and indication extension programs using the unique insights it has already generated across a broad range of complex chronic diseases.”
The Company has analyzed over 30 chronic diseases, building an in-house pipeline of programs, with assets being developed for partnered R&D and spinout collaborations. Its near-term projects include R&D research studies into the long-term effects of coronavirus (long COVID), ALS, non-T2 asthma, COPD, and multi-target discovery and validation deals with major pharmaceutical companies.
Welcoming Colin to the company, Steve Gardner, CEO of PrecisionLife, said: “Together with our recent financing, Colin’s appointment is a key step to making the transition from an AI R&D services company to a precision medicine drug discovery and healthcare focused company driven by our deep understanding of the biology that causes disease in key patient subgroups, and a rapidly growing pipeline of partnered and in-house programs of novel precision therapies and biomarkers.”
PrecisionLife has raised additional finance to fund its expansion and anticipates a final close of its Series A investment round in the coming months. The financing is being co-ordinated by leading specialist life sciences investment banking and corporate advisory firm WG Partners LLP.


Media Contact Information: 

Steve Gardner, CEO 
T: +44 (0)1865 575170

Press Contact
Charles Consultants 
Sue Charles 
T: +44 (0)7968 726585